Insider Selling: DexCom, Inc. (NASDAQ:DXCM) Insider Sells 250 Shares of Stock

DexCom, Inc. (NASDAQ:DXCMGet Rating) insider Steven Robert Pacelli sold 250 shares of the business’s stock in a transaction on Monday, April 25th. The shares were sold at an average price of $439.94, for a total transaction of $109,985.00. Following the sale, the insider now directly owns 35,425 shares of the company’s stock, valued at $15,584,874.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Steven Robert Pacelli also recently made the following trade(s):

  • On Wednesday, March 23rd, Steven Robert Pacelli sold 250 shares of DexCom stock. The shares were sold at an average price of $459.98, for a total value of $114,995.00.
  • On Wednesday, February 23rd, Steven Robert Pacelli sold 250 shares of DexCom stock. The shares were sold at an average price of $394.33, for a total value of $98,582.50.

DXCM opened at $413.02 on Thursday. DexCom, Inc. has a 52-week low of $318.45 and a 52-week high of $659.45. The company has a quick ratio of 4.62, a current ratio of 5.11 and a debt-to-equity ratio of 0.76. The company has a market cap of $40.53 billion, a P/E ratio of 266.47, a price-to-earnings-growth ratio of 7.95 and a beta of 0.94. The firm’s 50-day moving average price is $454.38 and its 200-day moving average price is $502.63.

DexCom’s stock is going to split on the morning of Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly minted shares will be payable to shareholders after the market closes on Thursday, June 9th.

DexCom (NASDAQ:DXCMGet Rating) last issued its earnings results on Thursday, February 10th. The medical device company reported $0.68 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.18). The firm had revenue of $698.20 million during the quarter, compared to analysts’ expectations of $698.66 million. DexCom had a net margin of 6.32% and a return on equity of 12.87%. DexCom’s quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 EPS. On average, research analysts anticipate that DexCom, Inc. will post 3.38 EPS for the current fiscal year.

DXCM has been the subject of several recent research reports. Citigroup decreased their price objective on DexCom from $660.00 to $630.00 in a report on Friday, February 11th. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating and set a $580.00 price objective for the company in a report on Friday, January 7th. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating and set a $452.00 target price for the company. in a report on Tuesday, February 1st. BTIG Research boosted their target price on shares of DexCom from $535.00 to $560.00 in a report on Monday, April 18th. Finally, Bank of America started coverage on shares of DexCom in a report on Wednesday, March 2nd. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, DexCom has a consensus rating of “Buy” and a consensus target price of $574.29.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Capital Research Global Investors boosted its position in DexCom by 55.2% in the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock valued at $1,275,020,000 after buying an additional 844,916 shares during the last quarter. Geode Capital Management LLC boosted its position in DexCom by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 1,868,331 shares of the medical device company’s stock valued at $1,000,773,000 after buying an additional 73,778 shares during the last quarter. Brown Advisory Inc. boosted its position in DexCom by 2.1% in the fourth quarter. Brown Advisory Inc. now owns 1,401,094 shares of the medical device company’s stock valued at $752,318,000 after buying an additional 29,161 shares during the last quarter. Norges Bank purchased a new stake in DexCom in the fourth quarter valued at approximately $410,670,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in DexCom in the fourth quarter valued at approximately $263,141,000. Hedge funds and other institutional investors own 95.14% of the company’s stock.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Read More

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.